跳至主要内容
临床试验/EUCTR2022-000617-13-ES
EUCTR2022-000617-13-ES进行中(未招募)1 期

A prospective, randomized, controlled trial assessing the effect of conversion from Tacrolimus-antimetabolite to Tacrolimus-mTor-inhibitors based immunosuppression to booster SARS-CoV-2-specific seroconversion after a fourth dose of SARS-CoV-2 mRNA vaccine in unresponsive Solid Organ Transplant recipients - TOR-VAX

Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)0 个研究点目标入组 50 人开始时间: 2022年3月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Patient’s age = 18 years
  • 2.Time of transplantation = 1 year
  • 3.Negative or very weak (<143BAU/ml) serological immune response after 3 doses of an mRNA SARS-CoV-2 vaccine
  • 4.Stable renal function with an estimated GFR = 40 mL/min/1.73 m2
  • 5.Urine protein to creatinine ratio < 0.8 g/g
  • 6.Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 35
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 15

排除标准

  • 1.Previous diagnosis of T-cell mediated or antibody-mediated rejection
  • 2.Previous seroconversion after any SARS-CoV-2 vaccine.
  • 3.Previous COVID-19 infection
  • 4.Presence of HLA donor-specific antibodies
  • 5.Active cancer excluding non-melanoma skin cancer
  • 6.Pregnancy

研究者

发起方
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)

相似试验